Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Visual system homeobox 1 (VSX1) is a paired-like homeodomain transcription factor involved in retinal development, particularly in the regulation of cone opsin gene expression and terminal differentiation of specific retinal bipolar cells[1][2][5][7]. It binds DNA at the locus control region of the red/green cone opsin gene cluster and acts primarily as a transcriptional repressor[1][2]. VSX1 is implicated in the pathogenesis of several corneal disorders, including keratoconus and posterior polymorphous corneal dystrophy, with disease-causing mutations following an autosomal dominant inheritance with variable expressivity[1][2][4][5]. No small molecule drugs or targeted therapies currently modulate VSX1 activity in clinical use, but genetic testing for VSX1 mutations serves as a biomarker for at-risk individuals, particularly in the context of corneal dystrophies and keratoconus[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Visual system homeobox 1 (VSX1).